Medivive

About Medivive

Medivive was founded in 2022 as a primary care telehealth platform that has increasingly focused on GLP-1 medication prescribing for weight management. Unlike platforms built exclusively around weight loss, Medivive positions itself as a broader telehealth provider that includes GLP-1 services as part of its clinical offerings. This primary care foundation means patients can potentially address multiple health concerns — not just weight — through the same provider relationship, which can improve care coordination and reduce the fragmentation that often characterizes telehealth experiences.

The platform prescribes both compounded semaglutide and compounded tirzepatide, with monthly costs ranging from $147 to $299 depending on the medication, dosage, and plan selected. This pricing is competitive within the compounded GLP-1 market, falling below many brand-name providers while remaining slightly above the most budget-oriented options. Patients should understand that compounded medications, while containing the same active ingredients, are not FDA-approved finished products and are prepared by outsourcing pharmacies rather than the original manufacturers (Novo Nordisk or Eli Lilly).

Medivive holds an A rating with the Better Business Bureau, indicating satisfactory business practices and complaint resolution. The company does not have a Trustpilot presence, so independent consumer review data at scale is limited. Our editorial team found the platform’s clinical process to be standard for the telehealth GLP-1 space: an online health questionnaire, asynchronous or synchronous provider review, and medication shipped directly to the patient. The support level is moderate, with provider check-ins and messaging access but without the dedicated dietitian coaching, lab testing, or behavioral programming offered by higher-tier platforms.

One advantage of Medivive’s primary care orientation is the potential for more holistic clinical oversight. Because the providers are trained in general medicine rather than operating solely as weight loss prescribers, they may be better positioned to identify contraindications, manage medication interactions, and address comorbidities that affect weight management outcomes. This clinical breadth is subtle but meaningful — particularly for patients with complex health profiles who need a provider comfortable managing multiple conditions simultaneously.

Medivive is a competent, moderately priced compounded GLP-1 provider with the added benefit of a primary care clinical foundation. The A BBB rating provides business credibility, and the pricing is fair for the compounded medication market. The platform does not stand out for clinical innovation or comprehensive support, but it delivers reliable GLP-1 access with solid medical oversight. Patients seeking brand-name medications, intensive coaching, or lab-integrated programs should consider higher-tier alternatives, while those wanting straightforward compounded GLP-1 access from a credible primary care platform will find Medivive a reasonable choice.

Medivive GLP-1 Medications

At a Glance